GLP1R and type 2 diabetes mellitus: FFAR1 and 4 are activated by medium- and long-chain free fatty acids and are putative targets for the treatment of type 2 diabetes by facilitating the secretion of glucose-stimulated insulin and the release of GLP-1 [203, 204].